51. Endoscopic Treatment for Post-Transplant Vesicoureteral Reflux.
- Author
-
Wang HH, Ding WF, Chu SH, Chiang YJ, Liu KL, Lin KJ, Lin CT, and Wang TM
- Subjects
- Child, Child, Preschool, Female, Humans, Male, Retrospective Studies, Treatment Outcome, Urinary Tract Infections etiology, Urinary Tract Infections surgery, Vesico-Ureteral Reflux etiology, Cystoscopy methods, Dextrans therapeutic use, Hyaluronic Acid therapeutic use, Kidney Transplantation adverse effects, Postoperative Complications surgery, Vesico-Ureteral Reflux surgery
- Abstract
Introduction: Vesicoureteral reflux (VUR) is one of the most common ureteric complications after kidney transplantation that might cause symptomatic infections which deteriorate graft function. Surgical reimplantation has been the standard treatment; recently, endoscopic injection has been an alternative approach. We report our endoscopic treatment results and analyze the long-term outcome, even in patients with less optimal graft function., Materials and Methods: A total of 16 patients and 19 symptomatic VUR were diagnosed at mean time of 88.3 months after their transplantation. The distribution of VUR grade was 1, 2, 8, 6, and 2 for grade I to V, respectively, with a mean VUR grade of 3.26 according to their voiding cystourethrogram images. Endoscopic Deflux injections were performed by a single urologist via rigid cystoscope with a beveled needle system. They were followed monthly thereafter., Result: The average number of admissions due to symptomatic urinary tract infection was 2.68/person, and the mean creatinine level before endoscopic treatment was 1.63 mg/dL. The amount of Deflux injection was 0.7 to 1.2 mL per affected ureter; the mean creatinine level after endoscopic treatment was 1.41 mg/dL. The eGFR remained stationary in both eGFR > 60 and eGFR < 60 mL/min groups with a clinical success rate of 75% in both groups., Conclusion: Endoscopic dextranomer-hyaluronic acid injection is a safe and feasible treatment option for VUR after kidney transplantation. Our data showed its efficacy in recipients whose eGFR is less than 60 mL/min., (Copyright © 2019 Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF